Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • JASN Podcasts
    • Article Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Editorial Fellowship
    • Editorial Fellowship Team
    • Editorial Fellowship Application Process
  • More
    • About JASN
    • Advertising
    • Alerts
    • Feedback
    • Impact Factor
    • Reprints
    • Subscriptions
  • ASN Kidney News
  • Other
    • ASN Publications
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • ASN Publications
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • JASN Podcasts
    • Article Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Editorial Fellowship
    • Editorial Fellowship Team
    • Editorial Fellowship Application Process
  • More
    • About JASN
    • Advertising
    • Alerts
    • Feedback
    • Impact Factor
    • Reprints
    • Subscriptions
  • ASN Kidney News
  • Follow JASN on Twitter
  • Visit ASN on Facebook
  • Follow JASN on RSS
  • Community Forum
UP FRONT MATTERSOccasional Observation
You have accessRestricted Access

Why Is the Mortality of Dialysis Patients in the United States Much Higher than the Rest of the World?

Robert N. Foley and Raymond M. Hakim
JASN July 2009, 20 (7) 1432-1435; DOI: https://doi.org/10.1681/ASN.2009030282
Robert N. Foley
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Raymond M. Hakim
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • View PDF
Loading

Comparing the outcomes among dialysis patients across countries is a formidable undertaking. Even with the existence of national dialysis registries, differences in case definitions, data ascertainment, completeness, case mix, and access to transplantation represent ever-present challenges to the validity of making such comparisons.

The Dialysis Outcomes and Practice Patterns Study (DOPPS) is a unique and highly informative resource1 and has several strengths, including a prospective design, longitudinal data collection, incorporation of prevalent and incident patients, and the use of harmonized methods in several countries and continents. The major objective of DOPPS is to quantify associations between practice patterns and patient outcomes, after accounting for differences in case-mix characteristics.

Studies reported by DOPPS consistently show a marked difference in crude mortality between different countries, with the mortality in the United States being one of the highest. For example, in 2003, DOPPS reported the crude 1-yr mortality rates were 6.6% in Japan, 15.6% in Europe, and 21.7% in the United States. After adjustment for age, gender, race, and 25 comorbid conditions, including cardiovascular comorbidity, the relative risk (RR) for mortality was 2.84 for Europe compared with Japan and 3.78 for the United States compared with Japan. Thus, variability in demographic and comorbid conditions at dialysis inception explains only part of the variances in mortality between countries.2

Another possible explanation for such differences in mortality is that it mirrors similar variability in background atherosclerotic cardiovascular disease (ASCVD) in the general population of each country. Cardiovascular disease is the major cause of mortality in the US dialysis population as well as in many other countries.

In a cross-sectional, multinational study and using data from the World Health Organization mortality database, a study by Yoshino et al.3 found not only a close correlation between all-cause mortality rates and ASCVD mortality in the general population but also that this correlation was even stronger for dialysis patients. The authors concluded that a portion of the variability in mortality rates observed between the dialysis populations of different countries is attributable to differences in background ASCVD mortality rates in the general population.

Other studies concluded that despite these differences in ASCVD in the general population and indeed after adjustment for differences in age, race, prevalence of ASCVD, diabetes, and other case-mix adjustments, regional differences in mortality (highest in the United States and lowest in Japan) remain. Importantly, differences across facilities within the same country suggest that practice patterns account for some of the variations in outcomes across countries. For example, a study by Goodkin et al.4 highlighted differences in rates of hepatitis B seroconversion that correlate with the number of patients per facility and use of protocols for treatment of patients with hepatitis B infections; for seroconversion of hepatitis C, greater employment of staff with at least 2 yr of formal nursing training was an important variable in practice pattern.

Could differences in other practice patterns explain the differences in mortality between countries and specifically account for the much higher mortality in the United States? We propose several types of explanations, including some that are well documented and others that could be considered “hypothesis generating.”

TYPES OF VASCULAR ACCESS AT INITIATION OF DIALYSIS

There is broad agreement that the type of vascular access used is an important determinant of survival in hemodialysis patients. Although the proportion of patients who have predialysis care by a nephrologist differs little between countries, there are large variations in the proportion of patients who initiate dialysis using an arteriovenous fistula, graft, or catheter. For example, a 2002 report from DOPPS highlighted that 83% of German dialysis patients initiated dialysis with a fistula, compared with 69% in Spain and only 15% in the United States.5 The “mirror image” of this low fistula rate is, of course, a high catheter rate. Indeed, the United States continues to have the highest rate of patients’ initiating dialysis with a catheter, with recent data from the US Renal Data System indicating that 82% of patients initiate dialysis with a catheter; after accounting for those who have a “maturing” fistula or graft, 65% of patients in the United States initiate dialysis with a catheter as the only access.6 Because there is broad consensus that dialysis catheters are a dominant driver of morbidity and mortality, these data suggest that the high rate of catheter in incident patients accounts for a significant part of the mortality difference across countries.

Another facet of such disparity in the type of vascular access at initiation of dialysis is that it partly reflects the interval between surgical referral and the availability of a fistula ready for cannulation. The median time to cannulation of a fistula varies from approximately 25 d in some countries to approximately 100 d in the United States.5

Failure of fistulas and synthetic grafts also results in temporary catheter insertions in prevalent patients. Indeed, DOPPS documents notable international variability in permanent access failure rates. For example, even with extensive adjustment for age, gender, and comorbidity, graft (hazards ratio 0.69) and fistula (hazards ratio 0.62) access failures are significantly less likely to occur in Europe than in the United States.7 Cross-sectional analyses from DOPPS reported a catheter prevalence of 24% in United States, compared with 10% in Europe, suggesting access management of established dialysis patients also explains some of the high catheter use and mortality seen in the United States.8

DOSAGE, TIME OF DIALYSIS, AND COMPLIANCE WITH TREATMENT REGIMEN

Comparisons from DOPPS suggest that dosage of dialysis, measured by single-pool Kt/V, is similar in Japan, Europe, and the United States with one publication reporting mean Kt/V values of 1.34, 1.36, and 1.41, respectively, and lowest 10th percentile values of 1.03, 1.09, and 1.13, respectively.9 Kt/V values for dialysis patients in the United States reported in DOPPS are likely to be representative, because US Renal Data System data for 2006 showed that only 7.2% of prevalent hemodialysis patients had Kt/V values <1.2.6

In contrast to the similarity in dosage of dialysis (Kt/V), differences in treatment time and ultrafiltration rates between countries are marked. In DOPPS II (2002 through 2004), for example, average treatment times were 235 min in Europe, 240 min in Japan, and 221 min in the United States; ultrafiltration rates were 8.4, 9.9, and 9.8 ml/h per kg, respectively.9 Differences in markers of treatment adherence are even more striking, with <1% of European and Japanese patients missing one or more dialysis session per month, compared with 7.9% in the United States; corresponding percentages for dialysis sessions that were shortened by at least 10 min were 9.8% in Europe, 5.7% in Japan, and as high as 19.6% in the United States.10 Several factors leading to missed and shortened dialysis sessions may be remediable, and missed and shortened treatments are likely to be important for quality and quantity of life in dialysis patients.10–12

NUTRITIONAL STATUS AND PRACTICE PATTERNS

In addition to the adverse outcomes associated with catheter use, the other most powerful predictor of mortality and hospitalization that may be actionable remains the level of albumin as an index of malnutrition.13 There are large variations among nutrition practice patterns for hemodialysis patients across several countries. For example, in several countries, it is a common practice to provide meals during each dialysis session, a strategy that may attenuate the negative protein balance that often occurs during dialysis.14 Meals are no longer provided in the United States; moreover, most dialysis facilities do not allow patients to bring their own food to eat while on dialysis because of concerns about aspiration and intradialytic hypotension.

Similarly, more than 10% of patients in European countries receive regular oral nutritional supplements, whereas, in the United States, such “free” oral supplements are severely restricted by government regulations.15 Such limitations to food intake in the United States, while patients are on dialysis for several hours, during which time they undergo 15 to 20 g of amino acid losses concurrent with removal of uremic molecules, may explain the difference in concentration of albumin in Europe (mean 3.92 g/dl) and the United States (mean 3.8 g/dl) with more than 60% of patients in the United States with albumin levels less than the target of ≥4.0 g/dl. Although serum albumin levels in hemodialysis patients are undoubtedly a reflection of inflammatory load, many intervention trials showed that they also reflect nutritional intake and that they are modifiable.16–21 Importantly, one of the prominent factors in increasing the inflammatory burden in dialysis patients is the use of catheters, and recent studies have documented an average improvement of 0.12 g/dl in albumin concentration after catheter removal.22 In observational studies, the importance of albumin is demonstrated by data suggesting that differences of as little as 0.2 g/dl are associated with marked differences in mortality and morbidity.23

STAFFING, LEVEL OF CARE, AND CONTACT TIME

Because of significant limitations in the reimbursement of dialysis procedures, staffing of dialysis facilities in the United States is predominately by technicians, who are often high school graduates with comparatively little training and who, until recently, were not required to undergo national technical competency examinations. Although there is a requirement that a nurse be present in each facility, the ratio of nurses to technicians (and patients) is highly variable and specified by only a few states. In contrast, staffing in European countries is predominantly by certified nurses and in Japan exclusively so.

Similarly, in Japan, there is a requirement for a physician to be present in each dialysis unit while most patients are on dialysis, whereas, in the United States, even the recent requirements outlined in the “Conditions for Coverage” promulgated by Centers for Medicare and Medicaid Services are that a patient be seen by a physician on dialysis once every 3 mo, with visits (in the office or dialysis unit) mandated at least once a month. Whether such differences in staffing expertise, ratio of staff to patients, or frequency of physicians’ rounding affect patient outcomes has not, to our knowledge, been explored adequately as a risk for poor outcome.

PATIENT EDUCATION

It is estimated that achieving guideline-based targets for dialysis dosage, hemoglobin and phosphate levels, catheter and interdialytic weight gain, and universal correction of serum albumin to >3.5 mg/dl would add an additional 143,617 life-years during a projected period of 5 yr, or approximately one third of a year per patient.24

Although changing patient behavior patterns is undoubtedly difficult, it is not impossible. A cluster-design randomized trial of an educational package about phosphorus food additives led to a clinically meaningful reduction in serum phosphorus levels.25 Both this trial and another observational study suggested that some of the excess mortality among dialysis patients in the United States is partly remediable by the most traditional of remedies: Contact time and a patient-centered, multidisciplinary approach. Thus, in the prospective Choices for Healthy Outcomes in Caring for ESRD (CHOICE) study, facility-level achievement of improved serum albumin, hemoglobin, calcium-phosphate product, and functional fistulas was more likely when sit-down rounds were carried out at a frequency of at least once per month. Indeed, sit-down rounds are associated with substantially lower hospitalization and mortality rates.26 Although supportive data are sparse, it seems obvious that factors such as staff numbers, skill sets, and patient contact time would influence outcomes.

Interventions that are responsive to the unique experiences of dialysis patients may have the best chance of being effective. For example, a recent nonrandomized, proof-of-concept study showed that regular chewing of gum containing chitosan, a naturally occurring phosphate-binding polymer, was able to bind salivary phosphate, which was followed by substantial reductions in serum phosphate in patients with previously recalcitrant hyperphosphatemia.27

OBSERVATIONS AND OPINIONS

Comparison of mortality across countries is an important tool to help us explore patient- and process-related factors that contribute to such mortality differences. Equally important, mortality comparison within each country, between the general population and the dialysis population, may be equally valuable, if not more so. An extreme opinion is that with dialysis providing the means to reduce uremic toxins to as low as possible and remove excess fluid and with the availability of erythropoietin, vitamin D, phosphate binders, and other medical interventions, the survival of dialysis patients should approach that of patients who undergo transplantation and eventually the normal population. Thus, instead of analyzing all of the comorbidity differences between the populations of countries, we should fund therapies and practice patterns that not only attenuate such differences between countries but, more important, also attenuate the large differences between the mortality of dialysis patients and the general population in the same country.6 Although this goal is a stretch, it is what we owe the patients entrusted to our care.

DISCLOSURES

None.

Footnotes

  • Published online ahead of print. Publication date available at www.jasn.org.

  • This commentary reflects the personal opinions of the authors and not necessarily the views of the entities where they work.

  • Copyright © 2009 by the American Society of Nephrology

REFERENCES

  1. ↵
    Young EW, Goodkin DA, Mapes DL, Port FK, Keen ML, Chen K, Maroni BL, Wolfe RA, Held PJ: The Dialysis Outcomes and Practice Patterns Study (DOPPS): An international hemodialysis study. Kidney Int 57[ Suppl 74]: S74– S81, 2000
    OpenUrlCrossRef
  2. ↵
    Goodkin DA, Bragg-Gresham JL, Koenig KG, Wolfe RA, Akiba T, Andreucci VE, Saito A, Rayner HC, Kurokawa K, Port FK, Held PJ, Young EW: Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol 14 : 3270– 3277, 2003
    OpenUrlAbstract/FREE Full Text
  3. ↵
    Yoshino M, Kuhlmann MK, Kotanko P, Greenwood RN, Pisoni RL, Port FK, Jager KJ, Homel P, Augustijn H, de Charro FT, Collart F, Erek E, Finne P, Garcia-Garcia G, Grönhagen-Riska C, Ioannidis GA, Ivis F, Leivestad T, Løkkegaard H, Lopot F, Jin DC, Kramar R, Nakao T, Nandakumar M, Ramirez S, van der Sande FM, Schön S, Simpson K, Walker RG, Zaluska W, Levin NW: International differences in dialysis mortality reflect background general population atherosclerotic cardiovascular mortality. J Am Soc Nephrol 17 : 3510– 3519, 2006
    OpenUrlAbstract/FREE Full Text
  4. ↵
    Goodkin DA, Young EW, Kurokawa K, Prütz KG, Levin NW: Mortality among hemodialysis patients in Europe, Japan, and the United States: Case-mix effects. Am J Kidney Dis 44[ Suppl 2]: 16– 21, 2004
    OpenUrlCrossRefPubMed
  5. ↵
    Rayner HC, Pisoni RL, Gillespie BW, Goodkin DA, Akiba T, Akizawa T, Saito A, Young EW, Port FK: Dialysis Outcomes and Practice Patterns Study: Creation, cannulation and survival of arteriovenous fistulae—Data from the Dialysis Outcomes and Practice Patterns Study. Kidney Int 63 : 323– 330, 2003
    OpenUrlCrossRefPubMed
  6. ↵
    US Renal Data System: USRDS 2008 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2008
  7. ↵
    Saran R, Dykstra DM, Pisoni RL, Akiba T, Akizawa T, Canaud B, Chen K, Piera L, Saito A, Young EW: Timing of first cannulation and vascular access failure in haemodialysis: An analysis of practice patterns at dialysis facilities in the DOPPS. Nephrol Dial Transplant 19 : 2334– 2340, 2004
    OpenUrlCrossRefPubMed
  8. ↵
    Pisoni RL, Young EW, Dykstra DM, Greenwood RN, Hecking E, Gillespie B, Wolfe RA, Goodkin DA, Held PJ: Vascular access use in Europe and the United States: Results from the DOPPS. Kidney Int 61 : 305– 316, 2002
    OpenUrlCrossRefPubMed
  9. ↵
    Saran R, Bragg-Gresham JL, Levin NW, Twardowski ZJ, Wizemann V, Saito A, Kimata N, Gillespie BW, Combe C, Bommer J, Akiba T, Mapes DL, Young EW, Port FK: Longer treatment time and slower ultrafiltration in hemodialysis: Associations with reduced mortality in the DOPPS. Kidney Int 1222– 1228, 2006
  10. ↵
    Saran R, Bragg-Gresham JL, Rayner HC, Goodkin DA, Keen ML, Van Dijk PC, Kurokawa K, Piera L, Saito A, Fukuhara S, Young EW, Held PJ, Port FK: Nonadherence in hemodialysis: Associations with mortality, hospitalization, and practice patterns in the DOPPS. Kidney Int 64 : 254– 262, 2003
    OpenUrlCrossRefPubMed
  11. DeOreo PB: Hemodialysis patient-assessed functional health status predicts continued survival, hospitalization, and dialysis-attendance compliance. Am J Kidney Dis 30 : 204– 212, 2007
    OpenUrlCrossRef
  12. ↵
    Leggat JE Jr, Orzol SM, Hulbert-Shearon TE, Golper TA, Jones CA, Held PJ, Port FK: Noncompliance in hemodialysis: Predictors and survival analysis. Am J Kidney Dis 32 : 139– 145, 1998
    OpenUrlCrossRefPubMed
  13. ↵
    Lacson E Jr, Wang W, Hakim RM, Teng M, Lazarus JM: Associates of mortality and hospitalization in hemodialysis: Potentially actionable laboratory variables and vascular access. Am J Kidney Dis 53 : 79– 90, 2009
    OpenUrlCrossRefPubMed
  14. ↵
    Veeneman JM, Kingma HA, Boer TS, Stellaard F, De Jong PE, Reijngoud DJ, Huisman RM: Protein intake during hemodialysis maintains a positive whole body protein balance in chronic hemodialysis patients. Am J Physiol Endocrinol Metab 284 : E954– E965, 2003
    OpenUrlCrossRefPubMed
  15. ↵
    Hecking E, Bragg-Gresham JL, Rayner HC, Pisoni RL, Andreucci VE, Combe C, Greenwood R, McCullough K, Feldman HI, Young EW, Held PJ, Port FK: Haemodialysis prescription, adherence and nutritional indicators in five European countries: Results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 19 : 100– 107, 2004
    OpenUrlCrossRefPubMed
  16. ↵
    Sharma M, Rao M, Jacob S, Jacob CK: A controlled trial of intermittent enteral nutrient supplementation in maintenance hemodialysis patients. J Ren Nutr 12 : 229– 237, 2002
    OpenUrlCrossRefPubMed
  17. Kloppenburg WD, Stegeman CA, Hovinga TK, Vastenburg G, Vos P, de Jong PE, Huisman RM: Effect of prescribing a high protein diet and increasing the dose of dialysis on nutrition in stable chronic haemodialysis patients: A randomized, controlled trial. Nephrol Dial Transplant 19 : 1212– 1223, 2004
    OpenUrlCrossRefPubMed
  18. Pupim LB, Flakoll PJ, Ikizler TA: Nutritional supplementation acutely increases albumin fractional synthetic rate in chronic hemodialysis patients. J Am Soc Nephrol 15 : 1920– 1926, 2004
    OpenUrlAbstract/FREE Full Text
  19. Akpele L, Bailey JL: Nutrition counseling impacts serum albumin levels. J Ren Nutr 14 : 143– 148
  20. Kalantar-Zadeh K, Braglia A, Chow J, Kwon O, Kuwae N, Colman S, Cockram DB, Kopple JD: An anti-inflammatory and antioxidant nutritional supplement for hypoalbuminemic hemodialysis patients: A pilot/feasibility study. J Ren Nutr 15 : 318– 331, 2005
    OpenUrlCrossRefPubMed
  21. ↵
    Rathod R, Baig MS, Khandelwal PN, Kulkarni SG, Gade PR, Siddiqui S: Results of a single blind, randomized, placebo-controlled clinical trial to study the effect of intravenous L-carnitine supplementation on health-related quality of life in Indian patients on maintenance hemodialysis. Indian J Med Sci 60 : 143– 153, 2006
    OpenUrlPubMed
  22. ↵
    Wystrychowski G, Kitzler TM, Thijssen S, Usvyat L, Kotanko P, Levin NW: Impact of switch of vascular access type on key clinical and laboratory parameters in chronic haemodialysis patients. Nephrol Dial Transplant February 19, 2009 [epub ahead of print]
  23. ↵
    Lacson E Jr, Ikizler TA, Lazarus JM, Teng M, Hakim RM: Potential impact of nutritional intervention on end-stage renal disease hospitalization, death, and treatment costs. J Ren Nutr 17 : 363– 371, 2007
    OpenUrlCrossRefPubMed
  24. ↵
    Port FK, Pisoni RL, Bragg-Gresham JL, Satayathum SS, Young EW, Wolfe RA, Held PJ: DOPPS estimates of patient life years attributable to modifiable hemodialysis practices in the United States. Blood Purif 22 : 175– 180, 2004
    OpenUrlCrossRefPubMed
  25. ↵
    Sullivan C, Sayre SS, Leon JB, Machekano R, Love TE, Porter D, Marbury M, Sehgal AR: Effect of food additives on hyperphosphatemia among patients with end-stage renal disease: A randomized controlled trial. JAMA 301 : 629– 635, 2009
    OpenUrlCrossRefPubMed
  26. ↵
    Plantinga LC, Fink NE, Jaar BG, Sadler JH, Coresh J, Klag MJ, Levey AS, Powe NR: Frequency of sit-down patient care rounds, attainment of clinical performance targets, hospitalization, and mortality in hemodialysis patients. J Am Soc Nephrol 15 : 3144– 3153, 2004
    OpenUrlAbstract/FREE Full Text
  27. ↵
    Savica V, Calò LA, Monardo P, Davis PA, Granata A, Santoro D, Savica R, Musolino R, Comelli MC, Bellinghieri G: Salivary phosphate-binding chewing gum reduces hyperphosphatemia in dialysis patients. J Am Soc Nephrol 20 : 639– 644, 2009
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top

In this issue

Journal of the American Society of Nephrology: 20 (7)
Journal of the American Society of Nephrology
Vol. 20, Issue 7
July 2009
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in JASN.
Enter multiple addresses on separate lines or separate them with commas.
Why Is the Mortality of Dialysis Patients in the United States Much Higher than the Rest of the World?
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Why Is the Mortality of Dialysis Patients in the United States Much Higher than the Rest of the World?
Robert N. Foley, Raymond M. Hakim
JASN Jul 2009, 20 (7) 1432-1435; DOI: 10.1681/ASN.2009030282

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Why Is the Mortality of Dialysis Patients in the United States Much Higher than the Rest of the World?
Robert N. Foley, Raymond M. Hakim
JASN Jul 2009, 20 (7) 1432-1435; DOI: 10.1681/ASN.2009030282
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • TYPES OF VASCULAR ACCESS AT INITIATION OF DIALYSIS
    • DOSAGE, TIME OF DIALYSIS, AND COMPLIANCE WITH TREATMENT REGIMEN
    • NUTRITIONAL STATUS AND PRACTICE PATTERNS
    • STAFFING, LEVEL OF CARE, AND CONTACT TIME
    • PATIENT EDUCATION
    • OBSERVATIONS AND OPINIONS
    • DISCLOSURES
    • Footnotes
    • REFERENCES
  • Info & Metrics
  • View PDF

More in this TOC Section

UP FRONT MATTERS

  • Collaboration between Dialysis Providers
  • Unfulfilled Expectations Open New Horizons: What Have We Learned about Volume-Regulated Anion Channels in the Kidney?
  • Polycystin-2 in the Endoplasmic Reticulum: Bending Ideas about the Role of the Cilium
Show more UP FRONT MATTERS

Occasional Observation

  • The Kidney Disease Screening and Awareness Program (KDSAP): A Novel Translatable Model for Increasing Interest in Nephrology Careers
  • Basic Research in Nephrology: Are We in Decline?
  • Where Is the Epidemic in Kidney Disease?
Show more Occasional Observation

Cited By...

  • Diabetic Kidney Disease: Challenges, Progress, and Possibilities
  • Bicarbonate Balance and Prescription in ESRD
  • In-Center Nutrition Practices of Clinics within a Large Hemodialysis Provider in the United States
  • Rehospitalizations and Emergency Department Visits after Hospital Discharge in Patients Receiving Maintenance Hemodialysis
  • Exploring the Association between Macroeconomic Indicators and Dialysis Mortality
  • Induced Pluripotent Stem Cells from Human Kidney
  • Performance Measurement in Chronic Kidney Disease
  • Blood Pressure and Mortality among ESRD Patients: All Patients Are Not Created Equal
  • Where Is the Epidemic in Kidney Disease?
  • Kidneys from Donors after Cardiac Death Provide Survival Benefit
  • International Hemodialysis Patient Outcomes Comparisons Revisited: The Role of Practice Patterns and Other Factors
  • ESRD as a Window into America's Cost Crisis in Health Care
  • Google Scholar

Similar Articles

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Annual Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Author Resources
  • Editorial Fellowship Program
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • JASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About JASN
  • JASN Email Alerts
  • JASN Key Impact Information
  • JASN Podcasts
  • JASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe to ASN Journals
  • Wolters Kluwer Partnership

© 2022 American Society of Nephrology

Print ISSN - 1046-6673 Online ISSN - 1533-3450

Powered by HighWire